

Haematologica  
HAEMATOL/2016/150656  
Version 2

The emerging role of immune checkpoint inhibition in malignant  
lymphoma

Ida Hude, Stephanie Sasse, Andreas Engert, and Paul J. Bröckelmann

Disclosures: IH and SS declare no conflict of interest, PJB declares an advisory role to Takeda, AE declares honoraria from Affimed, Bristol-Myers Squibb, Novartis, Takeda and research funding from Affimed, Bristol-Myers Squibb, Takeda.

Contributions: All authors contributed to manuscript writing and approved the final version.